Q1 EPS Estimates for USANA Health Sciences Cut by Sidoti Csr

USANA Health Sciences, Inc. (NYSE:USNA - Free Report) - Equities research analysts at Sidoti Csr dropped their Q1 2025 earnings per share estimates for shares of USANA Health Sciences in a research report issued on Wednesday, February 26th. Sidoti Csr analyst A. Lebiedzinski now anticipates that the company will post earnings per share of $0.71 for the quarter, down from their prior forecast of $0.77. The consensus estimate for USANA Health Sciences' current full-year earnings is $2.45 per share. Sidoti Csr also issued estimates for USANA Health Sciences' Q2 2025 earnings at $0.60 EPS, Q4 2025 earnings at $0.71 EPS, FY2025 earnings at $2.75 EPS, Q2 2026 earnings at $0.81 EPS and Q4 2026 earnings at $0.92 EPS.

USNA has been the subject of a number of other research reports. DA Davidson reduced their price objective on USANA Health Sciences from $38.00 to $36.00 and set a "neutral" rating for the company in a research report on Thursday. Sidoti downgraded USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, February 18th. Finally, StockNews.com downgraded USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a research report on Friday, February 14th.

USANA Health Sciences Trading Up 3.2 %

USNA traded up $0.91 during midday trading on Thursday, reaching $29.55. The company's stock had a trading volume of 299,854 shares, compared to its average volume of 166,624. The stock has a market cap of $563.22 million, a P/E ratio of 10.44, a PEG ratio of 0.93 and a beta of 0.87. The company has a fifty day simple moving average of $33.42 and a 200 day simple moving average of $36.49. USANA Health Sciences has a twelve month low of $27.71 and a twelve month high of $50.32.

Remove Ads

USANA Health Sciences (NYSE:USNA - Get Free Report) last released its earnings results on Tuesday, February 25th. The company reported $0.64 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.49 by $0.15. The firm had revenue of $213.61 million for the quarter, compared to analyst estimates of $208.82 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%.

Institutional Trading of USANA Health Sciences

A number of hedge funds have recently modified their holdings of USNA. R Squared Ltd bought a new position in shares of USANA Health Sciences during the 4th quarter worth approximately $28,000. Safe Harbor Fiduciary LLC bought a new position in shares of USANA Health Sciences during the 3rd quarter worth approximately $30,000. KBC Group NV lifted its position in shares of USANA Health Sciences by 96.6% during the 3rd quarter. KBC Group NV now owns 1,056 shares of the company's stock worth $40,000 after buying an additional 519 shares during the period. KLP Kapitalforvaltning AS bought a new position in shares of USANA Health Sciences during the 4th quarter worth approximately $83,000. Finally, Quantbot Technologies LP bought a new position in shares of USANA Health Sciences during the 4th quarter worth approximately $132,000. Institutional investors own 54.25% of the company's stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.